A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

NCT06349980 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: HLX53 (1000mg)
DRUG: HLX53 (2000mg)
DRUG: HLX10
DRUG: HLX04
OTHER: Placebo

Sponsor

Shanghai Henlius Biotech